Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.66
OCPNY's Cash to Debt is ranked lower than
65% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. OCPNY: 0.66 )
Ranked among companies with meaningful Cash to Debt only.
OCPNY' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.58 Max: N/A
Current: 0.66
Equity to Asset 0.37
OCPNY's Equity to Asset is ranked lower than
82% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. OCPNY: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
OCPNY' s Equity to Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.18 Max: 0.39
Current: 0.37
0.02
0.39
Interest Coverage 12.84
OCPNY's Interest Coverage is ranked lower than
54% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.00 vs. OCPNY: 12.84 )
Ranked among companies with meaningful Interest Coverage only.
OCPNY' s Interest Coverage Range Over the Past 10 Years
Min: 2.14  Med: 5.63 Max: 10.2
Current: 12.84
2.14
10.2
F-Score: 5
Z-Score: 2.54
WACC vs ROIC
7.38%
20.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 12.71
OCPNY's Operating margin (%) is ranked higher than
71% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. OCPNY: 12.71 )
Ranked among companies with meaningful Operating margin (%) only.
OCPNY' s Operating margin (%) Range Over the Past 10 Years
Min: 3.53  Med: 6.60 Max: 11.9
Current: 12.71
3.53
11.9
Net-margin (%) 0.25
OCPNY's Net-margin (%) is ranked lower than
59% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. OCPNY: 0.25 )
Ranked among companies with meaningful Net-margin (%) only.
OCPNY' s Net-margin (%) Range Over the Past 10 Years
Min: -11.71  Med: 1.51 Max: 5.41
Current: 0.25
-11.71
5.41
ROE (%) 0.56
OCPNY's ROE (%) is ranked lower than
61% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. OCPNY: 0.56 )
Ranked among companies with meaningful ROE (%) only.
OCPNY' s ROE (%) Range Over the Past 10 Years
Min: -62.3  Med: 7.00 Max: 25.76
Current: 0.56
-62.3
25.76
ROA (%) 0.19
OCPNY's ROA (%) is ranked lower than
57% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. OCPNY: 0.19 )
Ranked among companies with meaningful ROA (%) only.
OCPNY' s ROA (%) Range Over the Past 10 Years
Min: -9.32  Med: 1.12 Max: 4.73
Current: 0.19
-9.32
4.73
ROC (Joel Greenblatt) (%) 8.56
OCPNY's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. OCPNY: 8.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OCPNY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -28.73  Med: 12.95 Max: 45.88
Current: 8.56
-28.73
45.88
Revenue Growth (3Y)(%) -11.10
OCPNY's Revenue Growth (3Y)(%) is ranked lower than
81% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. OCPNY: -11.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OCPNY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12  Med: 0.30 Max: 19.4
Current: -11.1
-12
19.4
EBITDA Growth (3Y)(%) 1.80
OCPNY's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.90 vs. OCPNY: 1.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OCPNY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -6.90 Max: 41.5
Current: 1.8
0
41.5
EPS Growth (3Y)(%) -48.20
OCPNY's EPS Growth (3Y)(%) is ranked lower than
95% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. OCPNY: -48.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OCPNY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.4  Med: 2.50 Max: 135.6
Current: -48.2
-59.4
135.6
» OCPNY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OCPNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 676.15
OCPNY's P/E(ttm) is ranked lower than
99% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.55 vs. OCPNY: 676.15 )
Ranked among companies with meaningful P/E(ttm) only.
OCPNY' s P/E(ttm) Range Over the Past 10 Years
Min: 11.81  Med: 74.51 Max: 754.94
Current: 676.15
11.81
754.94
PE(NRI) 675.11
OCPNY's PE(NRI) is ranked lower than
99% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.55 vs. OCPNY: 675.11 )
Ranked among companies with meaningful PE(NRI) only.
OCPNY' s PE(NRI) Range Over the Past 10 Years
Min: 11.8  Med: 74.51 Max: 753.52
Current: 675.11
11.8
753.52
P/B 3.72
OCPNY's P/B is ranked lower than
62% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. OCPNY: 3.72 )
Ranked among companies with meaningful P/B only.
OCPNY' s P/B Range Over the Past 10 Years
Min: 2.12  Med: 3.93 Max: 20.67
Current: 3.72
2.12
20.67
P/S 1.82
OCPNY's P/S is ranked higher than
60% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. OCPNY: 1.82 )
Ranked among companies with meaningful P/S only.
OCPNY' s P/S Range Over the Past 10 Years
Min: 0.15  Med: 0.85 Max: 2.13
Current: 1.82
0.15
2.13
EV-to-EBIT 70.32
OCPNY's EV-to-EBIT is ranked lower than
92% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.75 vs. OCPNY: 70.32 )
Ranked among companies with meaningful EV-to-EBIT only.
OCPNY' s EV-to-EBIT Range Over the Past 10 Years
Min: -38.7  Med: 37.25 Max: 461.4
Current: 70.32
-38.7
461.4
EV-to-EBITDA 70.32
OCPNY's EV-to-EBITDA is ranked lower than
92% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.31 vs. OCPNY: 70.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCPNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.9  Med: 34.65 Max: 461.4
Current: 70.32
6.9
461.4
Current Ratio 1.56
OCPNY's Current Ratio is ranked lower than
75% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.64 vs. OCPNY: 1.56 )
Ranked among companies with meaningful Current Ratio only.
OCPNY' s Current Ratio Range Over the Past 10 Years
Min: 1.39  Med: 1.68 Max: 2.16
Current: 1.56
1.39
2.16
Quick Ratio 1.25
OCPNY's Quick Ratio is ranked lower than
67% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. OCPNY: 1.25 )
Ranked among companies with meaningful Quick Ratio only.
OCPNY' s Quick Ratio Range Over the Past 10 Years
Min: 1.11  Med: 1.34 Max: 1.75
Current: 1.25
1.11
1.75
Days Inventory 149.89
OCPNY's Days Inventory is ranked lower than
62% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.92 vs. OCPNY: 149.89 )
Ranked among companies with meaningful Days Inventory only.
OCPNY' s Days Inventory Range Over the Past 10 Years
Min: 54.63  Med: 72.88 Max: 136.79
Current: 149.89
54.63
136.79

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.21
OCPNY's Dividend Yield is ranked lower than
86% of the 140 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.39 vs. OCPNY: 0.21 )
Ranked among companies with meaningful Dividend Yield only.
OCPNY' s Dividend Yield Range Over the Past 10 Years
Min: 0.2  Med: 0.96 Max: 3.26
Current: 0.21
0.2
3.26
Dividend Payout 1.52
OCPNY's Dividend Payout is ranked lower than
90% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.39 vs. OCPNY: 1.52 )
Ranked among companies with meaningful Dividend Payout only.
OCPNY' s Dividend Payout Range Over the Past 10 Years
Min: 0.12  Med: 0.43 Max: 0.98
Current: 1.52
0.12
0.98
Yield on cost (5-Year) 0.22
OCPNY's Yield on cost (5-Year) is ranked lower than
86% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.83 vs. OCPNY: 0.22 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
OCPNY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.2  Med: 0.96 Max: 3.26
Current: 0.22
0.2
3.26
3-Year Average Share Buyback Ratio -8.60
OCPNY's 3-Year Average Share Buyback Ratio is ranked lower than
69% of the 127 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.40 vs. OCPNY: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OCPNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.6  Med: -0.10 Max: 0.2
Current: -8.6
-8.6
0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.32
OCPNY's Price/Tangible Book is ranked lower than
68% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.11 vs. OCPNY: 6.32 )
Ranked among companies with meaningful Price/Tangible Book only.
OCPNY' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.78  Med: 7.17 Max: 9.47
Current: 6.32
5.78
9.47
Price/Projected FCF 4.75
OCPNY's Price/Projected FCF is ranked lower than
81% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. OCPNY: 4.75 )
Ranked among companies with meaningful Price/Projected FCF only.
OCPNY' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.82  Med: 4.50 Max: 9
Current: 4.75
3.82
9
Price/Median PS Value 2.14
OCPNY's Price/Median PS Value is ranked lower than
89% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. OCPNY: 2.14 )
Ranked among companies with meaningful Price/Median PS Value only.
OCPNY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 0.99 Max: 2.39
Current: 2.14
0.38
2.39
Price/Peter Lynch Fair Value 132.76
OCPNY's Price/Peter Lynch Fair Value is ranked lower than
100% of the 50 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.47 vs. OCPNY: 132.76 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
OCPNY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 40.86  Med: 93.94 Max: 147.01
Current: 132.76
40.86
147.01
Price/Graham Number 13.75
OCPNY's Price/Graham Number is ranked lower than
94% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. OCPNY: 13.75 )
Ranked among companies with meaningful Price/Graham Number only.
OCPNY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.78  Med: 3.15 Max: 15.38
Current: 13.75
0.78
15.38
Earnings Yield (Greenblatt) (%) 1.41
OCPNY's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. OCPNY: 1.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OCPNY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.30 Max: 9.8
Current: 1.41
0.2
9.8
Forward Rate of Return (Yacktman) (%) 5.11
OCPNY's Forward Rate of Return (Yacktman) (%) is ranked lower than
66% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.62 vs. OCPNY: 5.11 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OCPNY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -39.6  Med: -28.95 Max: 5.1
Current: 5.11
-39.6
5.1

More Statistics

Revenue(Mil) $7220
EPS $ 0.06
Beta1.15
Short Percentage of Float0.00%
52-Week Range $30.36 - 41.73
Shares Outstanding(Mil)342.24

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:BDX, XPAR:EI, NYSE:BAX, NAS:ILMN, NYSE:BCR, OCSE:COLO B » details
Traded in other countries:OLY1.Germany, 7733.Japan,
Olympus Corp was incorporated in Japan on October 12, 1919. The Company is engaged in manufacturing and selling of precision machineries and instruments. The Company operates in four segments including Medical Business, Life Science and Industrial Business, Imaging Business, and Others. The Medical Business segment is engaged in manufacturing & selling of medical endoscopes, surgical endoscopes, endotherapy devices and other products including endoscopy systems includes videoscopes, video processors, light sources, and liquid crystal display (LCD) panels; peripheral equipment including image recording device, endoscope cleaning systems, and sterilization systems; surgical devices including surgical video endoscopy systems, peripheral devices for endoscopic surgery, and electrosurgical knives. The Life Science and Industrial Business segment is engaged in the manufacturing & selling of biological microscopes, industrial microscopes, industrial endoscopes, non-destructive testing equipment and other products. The Imaging Business segment is engaged in manufacturing and selling of digital cameras, voice recorders and other products. The Others business segment manufactures and sells biomedical materials and conducts system development and other business activities.
» More Articles for OCPNY

Headlines

Articles On GuruFocus.com
David Herro Comments on Olympus Oct 07 2014 
David Herro's Oakmark International Fund Third Quarter 2014 Letter Oct 07 2014 
T. Rowe Price Japan Fund’s Top 5 New Buys Jul 17 2013 
David Herro Comments on Olympus Corp. Apr 23 2013 
David Herro's Oakmark International Fund Q1 2013 Commentary Apr 23 2013 
Olympus' Efforts to Improve Corporate Governance Leave Room for More Sep 28 2012 

More From Other Websites
Olympus Corp. :OCPNY-US: Earnings Analysis: Q4, 2016 By the Numbers May 04 2016
Mitsubishi Motors says false mileage tests done since 1991 Apr 26 2016
Mitsubishi Motors says false mileage tests done since 1991 Apr 26 2016
Report: More infections from dirty scopes than estimated Apr 15 2016
Report: More infections from dirty scopes than estimated Apr 15 2016
[video]Olympus Teams Up With Sony for Surgical Big Screen TV Apr 09 2016
Scandal-plagued Toshiba sells medical unit to Canon Mar 17 2016
Scandal-plagued Toshiba sells medical unit to Canon Mar 17 2016
Whistleblower Delivers A Triple Whammy To Olympus; More Companies Might Get Hit Mar 04 2016
Olympus to pay at least $646 million to end US probes Mar 01 2016
Olympus to pay at least $646 million to end US probes Mar 01 2016
Olympus Will Pay $646 Million to End Kickback, Bribe Probes Mar 01 2016
Olympus settles with Japan whistleblower after 8-year battle Feb 18 2016
Olympus settles with Japan whistleblower after 8-year battle Feb 18 2016
Olympus Corp. Earnings Analysis: Q3, 2016 By the Numbers Feb 10 2016
Ex-Olympus CEO Woodford Sues Company for Breach of Contract Jan 15 2016
​Congressman wants SEC probe into Olympus over superbug outbreak Dec 23 2015
Medtronic-Samsung to Advance Neuromodulation Therapy Dec 14 2015
Becton, Dickinson Unveils BD FACSCelesta Flow Cytometer Dec 14 2015
St. Jude Medical Unveils Positive Data from SUNBURST Study Dec 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK